Dimitar Kalev

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 381 citations

Medicine, Oncology, Pharmacology +16

Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

Angelo Di Leo, Keun Seok Lee, Eva Ciruelos et al. · Cancer Research · 2017 · 55 citations

Medicine, Oncology, Pharmacology +17

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Salomon M. Stemmer, Nebojša Manojlović, Mihai Vasile Marinca et al. · Cancers · 2021 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A₃ adenosine receptor agonist (A₃AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

Salomon M. Stemmer, Nebojša Manojlović, Mihai Vasile Marinca et al. · Journal of Clinical Oncology · 2019 · 11 citations

Medicine, Oncology, Pharmacology +13